Ligand– tag –
-
Comprehensive Guide to Lipid Nanoparticles (LNPs): Key to mRNA Vaccine Success and Future RNA Therapeutic Delivery
Inside Therapeutics USA Overview Lipid nanoparticles (LNPs) are crucial nanodrug delivery systems for nucleic acids like mRNA and siRNA, vital for mRNA vaccine success and RNA therapeutics. This guide details LNP composition (ionizable l... -
MDPI Accelerates Non-Coding RNA Cancer Therapy with Organ-Selective LNPs: Achieving Precise Delivery to Liver, Spleen, and Lung
MDPI Switzerland Overview Non-coding RNA (ncRNA) therapeutics in cancer are advancing, with their efficacy significantly influenced by lipid nanoparticle (LNP) characteristics like lipid composition, particle size, and surface charge. Re... -
Transferrin-Conjugated Polymeric Nanoparticles via PISA Enhance BBB Transport and Doxorubicin Delivery for Glioblastoma Therapy
ACS Publications USA Overview Researchers have developed transferrin-conjugated polymeric nanoparticles, synthesized via polymerization-induced self-assembly (PISA), for enhanced blood-brain barrier (BBB) penetration and glioblastoma (GB... -
Structure-Aware AI Accelerates Next-Gen Drug Discovery: From 3D Molecular Geometry to Generative Biomolecular Design
Briefings in Bioinformatics | Oxford Academic UK Overview Structure-aware AI systems, leveraging graph neural networks, Transformer-based models, and diffusion-based generative models, are advancing next-generation drug discovery. These ... -
Multimodal Nanomaterials for Prostate Cancer Theranostics Advance, Integrating Precision Diagnosis and Therapy with PSMA-Targeted Platforms
International Journal of Nanomedicine (IJN) International Overview Research into multimodal nanomaterials for prostate cancer (PCa) theranostics is progressing, offering versatile platforms that integrate molecular imaging, biomarker det... -
Virus-Inspired Nanoparticles Revolutionize Drug and Gene Delivery, Overcoming Biological Barriers and Enhancing Cell-Specific Targeting for New Therapies
PMC International Overview Virus-inspired nanoparticles are emerging as a promising strategy for advanced drug and gene delivery. Viruses exhibit exceptional efficiency in overcoming biological barriers, targeting specific cells, and ind... -
Heart-Specific LNP Delivery for Myocardial Infarction Remains a Challenge: Conventional LNPs Accumulate in Liver, while Novel Lipid Engineering Targets Lungs and Spleen
American Heart Association Journals USA Overview Lipid nanoparticles (LNPs) are clinically validated non-viral vectors for delivering therapeutics like small molecules, mRNA, and siRNA; however, achieving heart-specific drug delivery for... -
2026 RNA Therapeutics Transformation: FDA Approves ASO Olezarsen, siRNA Fitusiran & Plozasiran, Ushering in Diverse Nucleic Acid Era
MiraScope Unknown Overview The year 2026 marks a significant transformation in RNA therapeutics, with multiple approvals solidifying antisense oligonucleotide (ASO) and siRNA therapies as established treatment platforms. Ionis Pharmaceut... -
Ribo Life Science’s siRNA Therapy Vortosiran Receives EMA Approval for Stroke Prevention Trial in Atrial Fibrillation Patients
Insight, China's Pharmaceutical Industry China Overview Ribo Life Science's siRNA therapy, vortosiran (BD4059), has received clinical trial approval from the EMA for stroke prevention in atrial fibrillation (SPAF) patients. Vortosiran is... -
Blood-Brain Barrier Drug Delivery Summit (B3DD) Convenes to Overcome CNS Therapeutic Hurdles
News-Medical.net USA Overview The Blood-Brain Barrier Drug Delivery Summit (B3DD) addressed critical challenges in CNS drug delivery, focusing on bypassing the brain's selective permeability. Advanced DDS research into nanoparticles, lip...
